Italy's Recordati sees no impact from potential U.S. pharma tariffs
By Giancarlo Navach
MILAN, Nov 7 (Reuters) -Italian drug maker Recordati RECI.MI is not afraid of potential new U.S. tariffs under president-elect Donald Trump as it expects them to have no impact on its rare diseases business, the company's chief financial officer said on Friday.
One of the main concerns in Europe and elsewhere from Trump's re-election victory this week is his campaign pledge to impose tariffs on a wide range of goods, including pharmaceutical products.
"Our business in the U.S. is only on rare diseases. I don't know what the intentions are, the rare disease business generally has different dynamics (from other potentially affected pharma products)," Luigi La Corte told Reuters.
Reporting by Giancarlo Navach, editing by Alvise Armellini, Gianluca Semeraro
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
